U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with P... (t care. The FDA clearance of O...)

HOME >> MEDICINE >> NEWS

U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass

Date:9/11/2009

t care."

The FDA clearance of OVA1 makes Quest Diagnostics the only diagnostic testing company to offer FDA cleared tests for ovarian cancer in the pre- and post-surgical settings. In addition to offering the OVA1 Test, Quest Diagnostics was the first laboratory company to provide a new lab test that the FDA cleared in the third quarter of 2008 as an aid for monitoring for recurrence of epithelial ovarian cancer.

The OVA1 Test will be available for physician use in the fourth quarter of this year.

Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer deaths in women.(2) Approximately 21,600 new cases of ovarian cancer will be diagnosed in the U.S. in 2009, and approximately 14,600 women will die of the disease.(3)

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) --- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

The OVA1 Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, s
'/>"/>

SOURCE Quest Diagnostics Incorporated; Vermillion
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Blue Cross Blue Shield of Michigan and Blue Care Network Announce Interim Policy to Cover H1N1 Vaccine Administration for Fully-Insured Groups During 2009-2010 Flu Season
2. Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)
3. Blue Shield of California to Cover H1N1 Flu Vaccine Administration for All Members
4. Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole
5. State of Kansas Streamlines COBRA Administration With Innovative Web-Based Solution
6. Veterans Administration Must Suspend Use of So-Called Death Book on Veterans, Malley Says
7. Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration
8. Sonic Innovations Awarded Contract From U.S. Veterans Administration
9. Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration
10. ARKRAY Statement Regarding U.S. Food and Drug Administrations Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology
11. Bayer Statement on U.S. Food and Drug Administration Advice for Patients: Serious Errors with Certain Blood Glucose Monitoring Test Strips

Post Your Comments:

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... of Autoimmune Diseases Therapeutics - Market ... Pipeline and Deals Analysis ... Summary ,, The author has ...

(Date:12/15/2009)... -- Hosted by the Technology-based Learning SIG of ... 2009,s best eLearning designs. This year nominees, ... categories. The Venza Group entry, a highly ... hotelier, was selected as the winner of the ... by the panel of distinguished judges. While ...

(Date:12/15/2009)... and CHENNAI, India, Dec. 15 ... the world leader in generic injectable pharmaceuticals, ... 524372, NSE: ORCHIDCHEM), a leading Indian pharmaceuticals ... antibiotics manufacturers globally, today announced an agreement ... finished-dosage form pharmaceuticals business for approximately $400 ...

(Date:12/15/2009)... following is being released by the American Health Information ... MS, RHIT, CCS, FAHIMA ,, AHIMA President ... us... ,, On behalf of the A-H-I-M-A Board of ... chief executive officer, Doctor Alan Dowling... ,, Back last ... someone who we knew could effectively replace ...

(Date:12/15/2009)... often treated with hormones, but when the tumours start ... reveals a thesis from the Sahlgrenska Academy, at the ... for new treatments for hormone-resistant prostate cancer. , Late ... cancer has spread, most patients are given hormone therapy. ... and the tumour shrinks. , "The problem is that ...

[0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business [0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST [0] More blood vessels in hormone-resistant prostate tumors

... songwriters and authors have described, our memories range from misty ... our lives. , Now, a study led by researchers at ... new insights into the specific components of emotional memories, suggesting ... remember and what we forget. , Reported in the ...

... reported in publications and news,outlets throughout the world, a ... at the summer games opening show,s musical,for a child ... the globe, sadly, the phenomenon of making judgments about,others ... nothing new., In a study published more than ...

... Shearon raises awareness and donations for breast cancer,research/programs, ... difference and do his part to end cancer, as ... disease. He set a goal of walking 18,marathons in ... awareness and dollars,for breast cancer research and programs at ...

... of how long a heart must stop beating before death ... new reports challenge current guidelines on how long after cardiac ... infant organ donor. , There,s no question that organ donation ... enough donor organs to save everyone on the transplant list. ...

... Ex-Hill Committee on Aging Chief Robert Weiner Says ... Street,Giveaway Turning Guarantee to Gamble, WASHINGTON, Aug. ... ex-U.S. House Committee on Aging Chief of Staff,Robert ... through,privatization are a cry-wolf, granny-you,re-on-your-own, Wall Street,giveaway which ...

... a.m. Eastern ... Time, ... today reports operational and,financial results for the quarter ended June 30, 2008 ... ), "Alseres made solid progress in our programs during the second,quarter," ...

Other Medicine News:Health News:Study finds that sleep selectively preserves emotional memories 2 Health News:Study finds that sleep selectively preserves emotional memories 3 Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2 Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2 Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3 Health News:Infant Heart Transplant Controversy Continues 2 Health News:Infant Heart Transplant Controversy Continues 3 Health News:Infant Heart Transplant Controversy Continues 4 Health News:Social Security's 73rd Anniversary 2 Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2 Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3 Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4 Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5 Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6

Study finds that sleep selectively preserves emotional memories Summer Games 'Swap' Raises Questions About Image, Oral Health More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius Infant Heart Transplant Controversy Continues Social Security's 73rd Anniversary Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

(Date:12/15/2009)... 15 Genomic Health, Inc. (Nasdaq: GHDX ... its Onco type DX® breast cancer test, a ... the likelihood of chemotherapy benefit and recurrence risk for ... at the 32nd Annual CTRC-AACR San Antonio Breast Cancer ... Antonio, TX. ,, "The breadth of data presented at ...

(Date:12/15/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that an overall survival benefit ... of surveyed European oncologists in their decision to ... the treatment of breast cancer. ,, The new ... European Trends in Targeted Therapies in Breast ...

(Date:12/15/2009)... -- Bend Research Inc. announced,today that its clients may ... used in technologies developed by the firm to enhance ... Bend Research clients may now reference a ... filings with the FDA, Bend Research officials said. , ... development and know it will assist our,clients in accelerating ...

Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7 For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2 For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3 Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2 Call for primary care reform from AAFP ACP and AOA 49392 1 Call for primary care reform from AAFP ACP and AOA 49392 2 Call for primary care reform from AAFP ACP and AOA 49392 3 Call for primary care reform from AAFP ACP and AOA 49392 4 Improved method developed to test carcinogen risk 8903 1 Improved method developed to test carcinogen risk 8903 2 Improved method developed to test carcinogen risk 8903 3 The straight poop on counting tigers 8900 1 The straight poop on counting tigers 8900 2

[0] Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations [0] For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe [0] Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient

... Pharmaleads has obtained from the,French Medicine Agency (AFSSAPS) ... I study with PL37, its lead compound for ... a major chronic pain condition, with an estimated,prevalence ... according to the most,recent surveys, with many causes ...

... England, October 2 Circassia Ltd, a specialty,biopharmaceutical ... critical,care, today announced the start of a further ... the field of cat allergy. The trial builds ... study, which demonstrated,the potential clinical benefits of the ...

Other Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2 Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2

Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology

Inquire...

500L...

... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...

Inquire...

Medicine Products:

Eppendorf Research Series 2100 Fixed-volume Pipette, 250 l Ovation BioNatural Pipette, one-stroke, fixed volume, 500L SoftGrip 500 L Fixed Volume Pipette Ovation BioNatural Pipette, two-stroke, fixed volume, 300L

U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with P...(t care. The FDA clearance of O...),Health